Stocklytics Platform
Asset logo for symbol AURA
Aura Biosciences
AURA42
$9.31arrow_drop_up3.88%$0.34
Asset logo for symbol AURA
AURA42

$9.31

arrow_drop_up3.88%

Performance History

Chart placeholder
Key Stats
Open$9.13
Prev. Close$9.00
EPS-1.73
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range9.00
9.55
52 Week Range5.99
12.35
Ratios
Revenue-
EBITDA Margin %-
EPS-1.73

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Aura Biosciences (AURA)

Aura Biosciences, Inc. (AURA) is a biotechnology company focused on the development of targeted therapies for cancer treatment. The company specializes in the development of a novel drug platform called Virus-Like Particle (VLP) technology, which has the potential to revolutionize the field of oncology. Aura Biosciences is dedicated to improving patient outcomes and quality of life through the development of innovative and effective therapies that target and destroy cancer cells while sparing healthy tissue.
One of the key strengths of Aura Biosciences is their smart analysis capabilities. They utilize advanced data analytics and machine learning algorithms to analyze large datasets and identify patterns and correlations that can provide valuable insights into the effectiveness of various treatments. This allows them to make data-driven decisions that optimize patient outcomes. The company's smart analysis capabilities set them apart from their competitors and give them a competitive advantage in the market.
Aura Biosciences, Inc. has a market capitalization of $XXX billion, making it a relatively small biotechnology company compared to some of its peers. However, despite its size, Aura Biosciences has managed to attract significant attention from investors and analysts due to its innovative approach to cancer treatment. The company's Virus-Like Particle (VLP) technology has shown promising results in preclinical and early-stage clinical trials, and there is excitement about its potential to revolutionize the treatment of various types of cancer. Aura Biosciences has also demonstrated a strong track record of securing funding and forming strategic partnerships, further validating the potential of its technology.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Elisabet de los Pinos Ph.D.
Headquarters
Boston
Employees
70
Exchange
NASDAQ
add Aura Biosciences to watchlist

Keep an eye on Aura Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Aura Biosciences's (AURA) price per share?

The current price per share for Aura Biosciences (AURA) is $9.31. The stock has seen a price change of $0.35 recently, indicating a 3.89% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Aura Biosciences (AURA)?

For Aura Biosciences (AURA), the 52-week high is $12.35, which is 32.65% from the current price. The 52-week low is $5.99, the current price is 55.43% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Aura Biosciences (AURA) a growth stock?

Aura Biosciences (AURA) has shown an average price growth of -1.69% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aura Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Aura Biosciences (AURA) stock price performance year to date (YTD)?

As of the latest data, Aura Biosciences (AURA) has a year-to-date price change of 3.1%. Over the past month, the stock has experienced a price change of -10.82%. Over the last three months, the change has been 25.98%. Over the past six months, the figure is 26.67%.
help

Is Aura Biosciences (AURA) a profitable company?

Aura Biosciences (AURA) has a net income of -$76.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$84.99M. Furthermore, the EBITDA is -$91.84M.
help

What is the market capitalization of Aura Biosciences (AURA)?

Aura Biosciences (AURA) has a market capitalization of $465.05M. The average daily trading volume is 9.28, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level